Welcome to our dedicated page for Synlogic news (Ticker: SYBX), a resource for investors and traders seeking the latest updates and insights on Synlogic stock.
Synlogic, Inc. (Nasdaq: SYBX) is a clinical-stage biopharmaceutical company at the forefront of synthetic biology and microbiome research. The company is pioneering the development of Synthetic Biotics™, which are engineered probiotic bacteria designed to perform specific therapeutic functions. These innovative biotherapeutics target a range of metabolic and rare genetic diseases, addressing unmet medical needs.
Using its proprietary Synthetic Biotics™ platform, Synlogic engineers probiotics to correct metabolic dysfunctions linked to various diseases. These therapeutics are primarily delivered orally, acting from the gut microbiome to address systemic issues. The company’s lead programs include treatments for rare genetic metabolic disorders such as phenylketonuria (PKU) and homocystinuria (HCU). Synlogic's pipeline also targets conditions like enteric hyperoxaluria, gout, and cystinuria.
One of Synlogic's flagship projects, labafenogene marselecobac (SYNB1934), is currently in a global, pivotal Phase 3 study for PKU, known as Synpheny-3. Additional candidates, such as SYNB1353 for HCU, are also progressing through clinical stages. The company collaborates with notable partners including Roche for inflammatory bowel disease (IBD) research and Ginkgo Bioworks for synthetic biology advancements.
Synlogic's commitment to innovative medicine is further demonstrated by its recent achievements. In December 2023, the company announced that SYNB1353, a potential treatment for HCU, would be presented at the International Conference on Microbiome Engineering. Additionally, Synlogic secured a $1 million subcontract from the Air Force Research Lab to develop a manufacturing process for a potential live probiotic product, extending a project initiated in 2020.
The company’s approach leverages well-characterized probiotics, such as Escherichia coli Nissle 1917, ensuring consistency, safety, and non-colonizing properties, which simplify oral administration and storage. Synlogic continues to expand its pipeline and research capabilities, driving forward its mission to transform the care of serious diseases through groundbreaking synthetic biology technologies.
Synlogic (SYBX) announced the pricing of an underwritten public offering, selling 10 million shares at $3.00 each, aiming for gross proceeds of $30 million. The offering will close around April 20, 2021, pending usual conditions. An additional 1.5 million shares may be purchased at the same price by the underwriter. The offering is conducted under a shelf registration statement effective since August 2018. The funds raised will support Synlogic's innovative Synthetic Biotic medicines targeting metabolic disorders, including Phenylketonuria and Enteric Hyperoxaluria.
Synlogic (Nasdaq: SYBX), based in Cambridge, Massachusetts, has commenced an underwritten public offering of its common stock as of April 15, 2021. All shares will be offered by the company, with a possibility for the underwriter to purchase an additional 15% of the shares within 30 days. The offering is contingent on market conditions, and specifics regarding size and terms are not guaranteed. The prospectus will be available on the SEC's website. Synlogic focuses on synthetic biology aimed at treating metabolic disorders.
Synlogic, Inc. (Nasdaq: SYBX) presented Phase 1 study data for SYNB1618, an oral treatment for Phenylketonuria (PKU), during the ACMG annual meeting. The results reveal that the solid oral formulation is well tolerated and metabolically active, effectively reducing plasma D5-Phe levels in healthy volunteers. This data supports further clinical development, with a Phase 2 trial, SynPheny, targeting adults with PKU expected to yield results in late 2021. PKU is a serious genetic disorder that requires early intervention to prevent neurological damage.
Synlogic, Inc. (Nasdaq: SYBX) presented data on its investigational drug SYNB1891 for treating solid tumors and lymphoma at the AACR annual meeting. The ongoing Phase 1 clinical trial demonstrated that SYNB1891 is safe and well-tolerated, with no dose-limiting toxicities reported. It showed target engagement through dose-dependent increases in serum cytokines and evidence of durable stable disease in two patients. The company is advancing the drug through further dose escalation and plans to report combination therapy data by the end of 2021.
Synlogic, Inc. (Nasdaq: SYBX) announced participation in virtual conferences, including the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021 and the Jefferies Microbiome-based Therapeutics Summit on April 22, 2021. CEO Aoife Brennan and Daniel Rosan will present at the Needham conference, while Brennan will engage in a Fireside Chat at the Jefferies Summit. These events aim to showcase Synlogic's synthetic biology platform and pipeline targeting metabolic disorders and immunology. Webcasts will be available on their website.
Synlogic, Inc. (SYBX) reported its 2020 financial results, revealing a consolidated net loss of $59.2 million, or $1.65 per share, compared to a net loss of $51.4 million in 2019. The company had no revenue in Q4 2020, down from $1.2 million in Q4 2019. However, significant advancements were noted in its clinical programs for Phenylketonuria (PKU) and Enteric Hyperoxaluria, with positive proof-of-mechanism data in humans. Synlogic anticipates important clinical readouts later this year and projected sufficient cash to fund operations into 2023.
Synlogic, Inc. (Nasdaq: SYBX) announced that SYNB8802 achieved proof of mechanism in its Dietary Hyperoxaluria study, demonstrating a 28.6% reduction in urinary oxalate levels compared to placebo. The treatment was well-tolerated in healthy volunteers, leading to the initiation of Part B, which will evaluate SYNB8802 in patients post-Roux-en-Y gastric bypass surgery. Data is expected in the second half of 2021. SYNB8802 aims to provide treatment for Enteric Hyperoxaluria, a condition with no approved therapies.
Synlogic, Inc. (NASDAQ: SYBX) announced it will release its fourth quarter and full year 2020 financial results on March 25, 2021, before market opening. A conference call will follow at 8:30 am ET, featuring a review of financial outcomes and corporate updates. Domestic callers can dial (844) 815-2882, while international callers should use (213) 660-0926, with conference ID 4897219. The call will be accessible via webcast on the Synlogic website, with a replay available for 30 days.
Synlogic, Inc. (Nasdaq: SYBX) announced the promotion of Dr. Caroline Kurtz to Chief Development Officer, overseeing portfolio strategy and the advancement of its Synthetic Biotic medicines, including SYNB1618 and SYNB8802. With 25 years of experience, Dr. Kurtz aims to drive clinical progress. Additionally, Daniel Rosan was promoted to Senior Vice President and Head of Finance, while Dr. Jamie Austin assumed leadership in Regulatory Affairs. The company focuses on metabolic disorders and looks to leverage its synthetic biology platform for therapeutic development.
On February 15, 2021, Synlogic (Nasdaq: SYBX) announced upcoming presentations by CEO Aoife Brennan and the executive team at several virtual banking and industry conferences. Key events include the BIO CEO & Investor Digital Conference on February 16, Cantor Fitzgerald Industry Panel on February 18, and the SVB Leerink Global Healthcare Conference on February 25. Synlogic focuses on synthetic biology to create medicines for metabolic disorders and other diseases. Archived webcasts will be available on their website for 30 days post-event.
FAQ
What is the current stock price of Synlogic (SYBX)?
What is the market cap of Synlogic (SYBX)?
What does Synlogic, Inc. specialize in?
What are Synthetic Biotics™?
What is Synlogic’s lead program?
What diseases are covered by Synlogic's pipeline?
How does Synlogic deliver its Synthetic Biotics™?
Who are Synlogic's research partners?
What recent achievements has Synlogic announced?
What makes Synlogic's probiotics unique?
What is SYNB1353 aimed at treating?
Where can I find more information about Synlogic?
